CDMO outperforms, formulations stumble; Zambia set to uplift FY28
The verdict, the claims that held up, the sharpest analyst exchanges, and the risks — the earnings call, decoded from the transcript.
Hold
confidence 6/10
Grade C
Hit 2 of 5 prior guides: CDMO double-digit ✓, API improved ✓, exports double-digit ✗, domestic IPM-level ✗, margins 14–15% ✓. Formulation guidance misses offset by core business delivery.
Cautiously Optimistic
next 1–2 quarters
Optimistic
multi-year
CDMO outperformance (+18.6% YoY, double-digit volumes) validates core strategy, but formulation misses (exports -1.5% vs prior double-digit guidance, domestic 7% vs IPM) and margin quality risks (one-time inventory/API gains) warrant caution. Zambia ramp and new oral capacity are structural catalysts, but execution risk remains.
₹1167 Cr
Revenue · +13.9% YoY₹101 Cr
Reported PAT · +56.1% YoYExpanding
Margins · vs guidance: MixedDid the claims hold up?
CDMO delivered double-digit volume growth this quarter
METCDMO revenue ₹964 Cr, +18.6% YoY, driven by volume and API price recovery
Marketing segments muted, expected to return Q3 onwards
OVERSTATEDDomestic branded +7.3% YoY, Int'l branded -1.5% YoY; below prior double-digit export guidance
Margins expected 14–15%, can incline to upper bracket
METQ1 margins 15.0%, but CFO confirmed driven by high API prices and Q4 inventory buildup—temporary drivers
API business improving toward profitability
METEBITDA -₹4 Cr (vs -₹6 Cr Q1 FY26, -₹12 Cr Q4 FY26); losses trending down but still negative
Zambia order on track for H2 delivery, ~₹240 Cr revenue, higher-teen margins
MET100+ products agreed with government, advanced stages, revenue recognition FY27 (updated from Q2 start to Q3/Q4)
Earnings quality
What changed since the last call
Zambia timing pushed
DowngradePrior call implied Q2 start; now Q3/Q4. Still ~₹240 Cr H2 FY27 and FY28 at higher-teen margin (vs prior 15–17%).
Margin outlook adjusted
NeutralReaffirm 14–15% but management caveated: Q1 benefited from one-time inventory gains and elevated API prices. Forward bias to upper bracket conditional on these staying.
Formulation growth guidance unmet
DowngradePrior: double-digit export growth. Q1 delivered: Int'l branded -1.5%. Domestic 7% (vs IPM ~2–3% + launches, implying management expected higher).
The Q&A
Analysts probed margin quality, API exit rationale, and formulation underperformance. Management defended API as 3-4 year investment with improving trajectory, restated margin guidance at 14–15%, attributed formulation softness to field-force buildup (short-term cost). No concessions on guidance; tone held.
CDMO growth, margins — Vivek Agarwal, Citigroup
AnsweredQ2 high-teens volumes. API prices volatile, moving upward. Margins target 14–15%, Q1 strong allows bias to upper bracket.
Margin beat driver — Vivek Agarwal, Citigroup
AnsweredAPI prices high; Q4 inventory buildup was strategic for margin protection. Both are tactical moves.
Formulation initiatives — Vivek Agarwal, Citigroup
AnsweredAkumentis: added 200 field, focused on Rx (gynaecology, cardiology, peds). Unosource: focus markets strategy, niche portfolio.
Formulation headwinds — Vivek Agarwal, Citigroup
AnsweredAkumentis: EBITDA drain from 200 field hires (15% increase, no PCPM yet). Unosource: one muted quarter; recovery Q2–Q3.
IPM volume outlook — Pooja
PartialHigh-teens Q3–Q1; Q2 strong high-teens. IPM 2–3%, volume is key lever. At least double-digit growth coming quarters.
Domestic growth mix — Anchal Maheshwari, Naredi Investment
PartialMix of launches, price, volume. Already taken price growth this quarter.
API business exit — Andrey (Cogito)
DodgedFully confident, 3–4 years invested, losses coming down. Question is how to improve profitability and scale, not exit.
Zambia/Europe margins, capacity — Andrey (Cogito)
AnsweredZambia/Europe: similar to current CDMO, maybe higher (higher teens). $25M (~₹240 Cr) H2 FY27, similar FY28. Spare capacity strategic; can do 55–60%, now at 50%.
Senior talent recruitment — Andrey (Cogito)
PartialCompany well-run by professionals. Always need fresh blood but ample leadership. Stem from homegrown talent.
Workforce quality feedback — Andrey (Cogito)
DefensiveSandeep denied; said have M.Pharms, PhDs, doctorates, best % in industry. Andrey persisted: feedback from shareholders and ex-employees.
Zambia timing — Bhavin Chheda, Enam Holdings
AnsweredMaintained Q3, maybe some Q4. Advanced stages with 100+ products. This fiscal will recognize revenue.
Cash position — Bhavin Chheda, Enam Holdings
AnsweredYes, net of debt.
Oriflame acquisition rationale — Praveen Jayaraman, Avendus Spark
AnsweredNiche formulation strategy. Expand cosmeceutical capacity, venture into color cosmetics. Build on R&D moat. Tap fast-growing BPC market.
Capacity optimization with new orders — Praveen Jayaraman, Avendus Spark
AnsweredNo subcontracting. Gross margins >40%, don't want to lose. Business via basket approach. Setting up Baddi facility by year-end for oral boost.
Gross margin drivers — Akshay Shah, VVD Asset Managers
AnsweredVery limited inventory gains. Mostly high-value products. API also improved (90%+ COGS → 75% COGS).
Gross margin sustainability — Akshay Shah, VVD Asset Managers
AnsweredYes, expectation. API and CDMO improvements supporting.
API EBITDA trajectory — Akshay Shah, VVD Asset Managers
AnsweredNo seasonality. Completely in control. Expected to gradually come down toward breakeven.
Volume growth FY27 — Divya Daga, VGSPL
PartialDifficult to quantify. Industry sustains. Expect at least double digits FY27/FY28. Baddi capacity by year-end supports future.
M&A appetite — Divya Daga, VGSPL
AnsweredHave ₹1,600 Cr cash, non-leveraged. Look at value accretion and business rationale. Cautious on very large bids, but have ammunition.
API pricing pass-through, customer inventory — Abdulkader Puranwala, ICICI Securities
AnsweredCost-plus model—input material prices passed at each PO. Inventory behavior varies by customer. 5–6 months into inflation, secondary market picking up, volume still growing.
API profitability guidance — Abdulkader Puranwala, ICICI Securities
AnsweredYes. Target monthly EBITDA positive by end Feb/March, then next year positive P&L contribution.
Cash deployment — Abdulkader Puranwala, ICICI Securities
Answered98% in fixed deposits, nationalized banks. No debt, net worth >₹3,400 Cr. Will pursue acquisitions if synergies, else secured for business.
Sales force productivity — Akshay Shah, VVD Asset Managers
AnsweredLower than average, correct. Strategy: strong clinical presence, focused products. Expansion for geographies/HQs. PCPM is mature metric; they're in build phase. Will eventually reach/surpass industry but in investment mode.
Guidance
CDMO high-teens volume growth Q2 onwards
HighQ2 already 'extremely encouraging'; volumes sustained; API prices moving upward. Precedent: Q3–Q4 FY26, Q1 FY27 all high-teens.
Zambia ~₹240 Cr (≈$25M) in H2 FY27; similar FY28
High100+ products finalized with government; advanced stages. Expected Q3 or some Q4 revenue recognition this fiscal.
European business to kick off next financial year
MediumPilots underway; no specific revenue quantum yet; timeline next FY only.
EBITDA margin 14–15% target for FY27, bias upper bracket
MediumQ1 at 15% but management caveated: API prices high, Q4 inventory buildup tactical. If prices normalize, 14% risk.
Zambia/Europe margins in 'higher teens' vs current CDMO
MediumVaguer than prior '15–17%' range. CDMO margins currently ~16.9% (₹163/₹964); 'higher teens' suggests 18–19%.
Baddi oral facility live by end FY27
HighAnnounced; expected to 'significantly boost oral manufacturing capabilities' but capex quantum not disclosed ('still discussing').
Risks the call surfaced
Margin sustainability
Medium15% margin driven by high API prices and Q4 inventory buildup for protection. If API prices normalize (management acknowledged volatility) or inventory liquidates, margins could compress to 14% or below.
Formulation execution risk
MediumDomestic branded revenue +7.3% YoY but EBITDA fell 25% due to 200 new field staff (15% increase). International branded fell 1.5% YoY. Both missed prior double-digit export guidance; recovery delayed to Q3.
CDMO customer concentration
MediumCDMO is ₹964 Cr (82.7% of total revenue). No breakdown of customer concentration disclosed. Loss of major customer would materially impact revenue and profitability.
API business profitability
LowAPI EBITDA -₹4 Cr (improving from -₹6 Cr Q1 FY26, -₹12 Cr Q4 FY26), but target is monthly breakeven by end FY27. Losses must halve again in one quarter for target; execution risk remains.
Zambia delivery timing
LowZambia order pushed from Q2 start to Q3/Q4 revenue recognition. ₹240 Cr (≈$25M) expected in H2 FY27, but no revenue yet. Supply chain delays or regulatory friction could slip to next year.
Talent quality feedback
LowAnalyst (Andrey) surfaced feedback from minority shareholders and ex-employees that many staff are 12th-class pass, potentially limiting execution quality. Management denied but defensive tone.
Management
Score 6/10. Transparent on drivers (inventory gains, API prices) but vague on quantified FY27 guidance (volumes, exports). Candid on formulation headwinds (field force ROI unproven). Avoided specific guidance on API profitability timeline beyond 'monthly breakeven by end FY27'. CDMO beat guidance (+18.6% vs double-digit target); API losses trending down (credible path). Formulations missed: exports -1.5% (vs prior double-digit), domestic 7.3% (below IPM potential). Field force added but EBITDA fell 25%. Zambia timing revised (Q2→Q3/Q4).
1 · Q3-Q4 FY27
Zambia revenue recognition (~₹240 Cr); European bio business pilots
2 · End FY27
Baddi oral facility goes live; API monthly EBITDA breakeven target
3 · Q2-Q3 FY27
Domestic branded and Unosource expected to return to growth
Zambia ramp and new oral capacity are structural catalysts, but execution risk remains.
Akums Q1FY27: consolidated PAT surges 56% YoY to ₹101 Cr as margins expand, exports miss
PAT +56.12% YoY · revenue +13.93% · margins expanding
₹1,166.63 Cr
+13.93% YoY
₹100.98 Cr
+56.12% YoY
8.44%
+2.3pp YoY
₹6.53
Akums Drugs' consolidated Q1 FY27 (June quarter) print showed profit after tax of ₹100.98 Cr, up 56.1% YoY from ₹64.69 Cr and up 24.2% QoQ from ₹81.34 Cr, on revenue of ₹1,166.63 Cr, up 13.9% YoY and roughly flat (+0.8%) QoQ. Net margin expanded to 8.44% from 6.16% a year ago and 6.82% last quarter; operating margin (EBITDA/revenue) rose to an estimated ~15.0% from ~12.6% YoY. Neither the current nor the year-ago quarter carried exceptional items, so the growth is on a clean, unadjusted basis.
Q1 FY-2027 vs prior quarters
The drivers line up closely with management's May 2026 guidance. CDMO external revenue grew 18.6% YoY to ₹964.21 Cr, ahead of the guided "double-digit volume growth." The API segment's loss narrowed to ₹8.15 Cr from ₹10.65 Cr a year ago and from ₹16.75 Cr last quarter, consistent with management's stated goal to "significantly reduce losses" — though full-year API profitability remains unconfirmed, per management's own earlier caveat. Domestic branded formulations grew 7.3% YoY, broadly tracking the guided IPM-level pace. International branded formulations (exports), however, fell 1.5% YoY to ₹34.55 Cr against a guided double-digit export growth target — a clear miss on that specific line even as the consolidated headline beat.
The stock went into the print at ₹697.45, up 6% over the past month of trading.
For context: PAT has now risen for 3 consecutive quarters.
Management provided positive guidance for FY27, expecting double-digit volume growth in the CDMO business driven by existing customers and new international contracts. They anticipate sustained or improved API prices and are targeting IPM-level growth for the domestic branded formulation business, with double-digit gro
— This quarter: met
A divergence worth flagging: standalone (parent-only) PAT was almost flat YoY at ₹44.84 Cr (-0.06%) even as standalone revenue grew 18.0% YoY — nearly all of the consolidated profit growth is coming from subsidiaries, not the parent entity. No quarter-specific street consensus could be located; full-year FY27 analyst PAT-growth estimates sit around 15-20%, a pace this quarter's +56% YoY print is running well ahead of, though a single quarter isn't directly comparable to an annual estimate. The board also disclosed a fresh income-tax demand of ₹156.02 Cr for the FY19-25 block period tied to the 2025 search-and-seizure action (company has appealed, deposited ₹4.70 Cr under protest, and maintains no adjustment is needed), and subsequent to quarter-end, subsidiary Pure and Cure Healthcare agreed to acquire Oriflame India's manufacturing business for ₹56 Cr, extending the group into color cosmetics, skincare and wellness.
W1
Export growth recovery: management guided double-digit export growth for FY27 but Q1 exports fell 1.5% YoY to ₹34.55 Cr — watch for a rebound in coming quarters
W2
API segment path to profitability: loss narrowed to ₹8.15 Cr this quarter from ₹10.65 Cr YoY, but management has said full-year profitability is not yet guaranteed
W3
CDMO margin trajectory: management guided margins similar to current levels near-term, improving to high-teens in the medium term as new international contracts ramp
Clean tables, no exceptional items in current or year-ago quarter (unadjusted YoY compare is valid). Consolidated PAT of ₹100.98 Cr includes ₹0.97 Cr non-controlling interest (owners' share ₹100.01 Cr, EPS computed on owners' share basis). Fresh IT search-and-seizure tax demand of ₹156.02 Cr (consol.) / ₹60.09 Cr (standalone) for the Apr'18-Mar'25 block period disclosed; under appeal, no provision made. All figures converted from ₹ million (÷10) to ₹ Crore.
CDMO shines; margins on borrowed time
Profit jumped 56% and operating margins hit 15%—a 238 bps beat. But 22 minutes into the call, the CFO revealed both rest on high API prices and Q4 inventory buildup, neither of which will hold. Formulations stumbled. The real quarter is narrower than the headline.
The real quarter: one engine firing, one in maintenance mode
Headline profits jumped 56% and operating margins hit 15%, a 238 bps surge from Q1 FY26. Impressive on paper. But 22 minutes into the earnings call, Sahil Maheshwari (Head Strategy) casually revealed the asterisk: "Q4, we also had built some inventory to protect ourselves… These are strategic calls we took, which helped us secure our margins." And when pressed on margin beat drivers, he noted API prices have been elevated for six months. Net out those two tailwinds—inventory liquidation and API price normalization—and the quarter loses 100–150 bps of the margin beat. It's real growth, but the story is narrower than the headline.
The two-speed quarter is clear in the segment mix. CDMO, which accounts for 83% of revenue (₹964 Cr), delivered +18.6% YoY growth on volume and API price recovery—that's the bullish case. But Akumentis (domestic branded) and Unosource (exports) grew just 7.3% and fell 1.5% YoY respectively, missing prior guidance for double-digit export growth by 1,500 basis points. Worse, Akumentis EBITDA fell 25% despite topline growth, because the company added 200 field staff (a 15% increase) with no PCPM payback yet. Formulations aren't broken, they're in investment mode—and the ROI meter hasn't started.
₹964 Cr
+18.6% YoY | 83% of revenue | EBITDA +36.8%
₹115 Cr
+7.3% YoY | EBITDA -25% YoY
₹35 Cr
-1.5% YoY | Missed double-digit guidance
-₹4 Cr EBITDA
Improving from -₹6 Cr Q1 FY26, -₹12 Cr Q4
What management claimed—and what the numbers say
CDMO delivered double-digit volume growth this quarter
CDMO ₹964 Cr (+18.6% YoY) on volume and API price recovery. Management confirmed 'high-teens' volumes Q2 onwards.
Supported
Marketing segments muted, expected to return Q3 onwards
Domestic +7.3% (vs IPM 2–3%), Int'l -1.5% (vs prior double-digit export guidance). Both missed. Recovery claimed Q3, unverified.
Overstated
Margins expected 14–15%, can bias to upper bracket given Q1 strength
Q1 margins 15.0%, but CFO confirmed driven by high API prices and Q4 inventory buildup—both tactical. Forward bias 'conditional' on these staying.
Supported (with caveat)
API business improving toward profitability
EBITDA -₹4 Cr (vs -₹6 Cr Q1 FY26, -₹12 Cr Q4 FY26). Losses halving; target monthly breakeven by year-end. Path credible but not yet realized.
Supported
Zambia order on track for H2 delivery, ~₹240 Cr revenue, higher-teen margins
100+ products finalized with government, 'advanced stages'. Timing revised: prior Q2 start → now Q3 or some Q4. Revenue recognition FY27 maintained.
Supported (with timing slip)
What changed on this call
Three material shifts from prior guidance:
Zambia timeline slipped. Prior call implied Q2 revenue start. Now Q3 or Q4. Still ~₹240 Cr H2 FY27 and similar FY28 at 'higher-teen' margins (vs prior 15–17% specificity).
Export guidance unmet. Prior: double-digit growth. Q1: -1.5%. Domestic also undershot (7.3% vs IPM potential). Management expects Q3 recovery, but the miss is real and resets the narrative.
Margin quality flagged. Reaffirmed 14–15% for FY27, but caveated: Q1 benefited from API price peak and Q4 inventory buildup. If either normalizes, margins compress toward 14% or below.
How the market reads it
The stock rose +4.68% on day 1 post-result and held at +7.53% by day 3, pricing in the headline beat and CDMO strength. It's near its all-time high of ₹775 (currently ₹749.95, down 3.2%), up 83% from the 52-week low. Trend is bullish, volume increasing.
But FII ownership tells a more cautious story. Holdings ticked up just +0.54 percentage points to 1.91% in Q1, despite the earnings beat—a modest vote of confidence. Compare that to Q1 FY26, when FII held 4.24%, and Q4 FY25's 5.77%: a decline of 290 bps over a year. The drift downward, even as the stock rallies toward ATH, suggests foreign money is taking profits into strength rather than adding on the quarter. DII marginally trimmed (-0.91pp to 13.44%). Promoter steady at 75.26%. The market's +7.53% pop on day 3 says the headline is priced in. FII trimming despite strength is a quiet warning: good quarter, but execution risk on formulations and margin sustainability keeps it a hold, not a high-conviction buy.
The bull-bear ledger
CDMO +18.6% YoY on volume and pricing recovery; 83% of revenue provides stable earnings core
EBITDA margins +238 bps; CDMO segment EBITDA +36.8% YoY demonstrates pricing power at 50% utilization
API losses trending down predictably toward profitability; monthly breakeven target by year-end credible
Zambia finalized with 100+ products; ₹240 Cr revenue potential in H2 FY27 at higher-teen margins if delivered
Balance sheet fortress: ₹1,616 Cr net cash, zero debt, net worth >₹3,400 Cr; ammunition for M&A
Margin beat is on temporary drivers (API prices + inventory). If either normalizes, 15% compresses to 14% or below, missing guidance.
Formulation segments (Akumentis + Unosource, ₹150 Cr combined) grew blended ~5%, well below prior double-digit export target.
Akumentis EBITDA fell 25% YoY despite 7% revenue growth; 200 new field staff added with no PCPM payback yet. ROI unproven.
CDMO concentration at 83% of revenue; no customer concentration disclosed. Volume slowdown would materially impact growth.
Zambia timing slipped Q2→Q3/Q4. Execution risk on supply chain, regulatory approvals, and volume ramp.
Ranked risks
Margin sustainability
High15% margin is 238 bps above Q1 FY26, but CFO attributed it to API price peak and Q4 inventory buildup. Both are tactical. If API prices normalize (management noted volatility) or inventory liquidates, margins compress toward 14% or lower, missing forward guidance.
Formulation execution stall
HighDomestic EBITDA fell 25% YoY despite 7% revenue growth due to 200 new field hires. Akumentis claimed Q3 recovery, but no metrics on PCPM or ROI timeline. A ₹115 Cr segment betting on unproven deployment strategy.
CDMO customer concentration
MediumCDMO is ₹964 Cr (83% of revenue and 87% of EBITDA); no customer concentration breakdown disclosed. Loss of a major customer would materially impact revenue and profitability. Competitive intensity on margins if customer mix shifts.
API profitability timeline
LowEBITDA -₹4 Cr with monthly breakeven targeted by year-end. Losses halving each quarter—credible if non-cepha product mix (linezolid, montelukast) holds and gross margin improvement from 90% to 75% COGS sustains. But if trend breaks, breakeven slips into FY28.
Zambia delivery risk
LowTimeline pushed from Q2 start to Q3/Q4 revenue recognition. ₹240 Cr (~$25M) is modest vs ₹1,167 Cr total revenue. Supply chain or regulatory delays possible; FY28 ramp is the higher-stakes test of delivery capability.
The debate
What to watch next
1 · CDMO organic growth without API tailwinds
Q2 will show whether CDMO's +18.6% is sustainable if API prices normalize. Management guided 'high-teens' volumes Q2 onwards. If Q2 delivers that organic (volume-driven, not price-driven), the bull case gains credibility and rules out a one-quarter blip.
2 · Formulation recovery timing and EBITDA swing
Akumentis EBITDA needs to swing positive from the -25% bleed this quarter. Management claims Q3 recovery. Watch for PCPM data, field staff productivity metrics, or commentary on deployment ROI that validates the 200-hire spend.
3 · Zambia revenue recognition and Baddi facility commissioning
If Q3 or Q4 revenue from Zambia is recognized, it validates the ₹240 Cr H2 guidance and proves delivery capability. Baddi facility commissioning by year-end signals domestic oral upside is no longer vague—and gives formulations a new growth engine.
The number to track
From here: CDMO segment EBITDA margin. Currently 16.9% (₹163 Cr on ₹964 Cr revenue), up from ~15.4% YoY. If this expands further as API mix stays high and capacity utilization improves toward 60%, the 14–15% consolidated margin guidance is credible. If it compresses toward 15–16% (API price normalization, competitive pressure), the margin beat unwinds and FY27 guidance is at risk. That one metric tells you whether margins are structural or temporary—and whether the stock re-rates or rolls over into 2027.
CDMO shined; formulations stumbled; margins borrowed. The +7.53% pop on day 3 says the headline is priced in, but FII trimming despite strength is a quiet alert. Management held guidance but offered no upside—a cautious posture after formulation misses. Execution on Q2 CDMO growth, Q3 formulation recovery, and H2 Zambia revenue recognition will settle whether this is a step-change or a steady-state holding with margin risk.